Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
54 hedge funds and large institutions have $168M invested in Galera Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
6% more funds holding
Funds holding: 51 → 54 (+3)
15% less capital invested
Capital invested by funds: $197M → $168M (-$28.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$10M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$2.35M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$1.04M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$988K |
| 5 |
BlackRock
New York
|
+$601K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$9.39M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.49M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.58M |
| 4 |
PA
Perceptive Advisors
New York
|
-$772K |
| 5 |
Millennium Management
New York
|
-$411K |
GRTX Hedge Fund Activity: Q1 2021 in Review
54 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q1 2021, worth a combined $168M — down 15% from $197M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GRTX positions and 4 closed out — a net gain of 3 holders — while 18 added to existing stakes and 16 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $10M. The largest seller was VR Adviser, exiting entirely with an estimated $9.39M sold.
- 54 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q1 2021, up from 51 in Q4 2020.
- Funds reported $168M of Galera Therapeutics, Inc. Common Stock stock for Q1 2021, down 15% quarter-over-quarter.
- 7 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q1 2021 and 4 closed out, a net change of +3 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q1 2021 was AIGH Capital Management, an estimated $10M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q1 2021 was VR Adviser, an estimated $9.39M sold.
Based on aggregated 13F filings for Q1 2021.